NICE Recommends Biogen’s Multiple Sclerosis Drug Vumerity

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Biogen’s Vumerity (diroximel fumarate) for National Health Service (NHS) use for the treatment of relapsing-remitting multiple sclerosis.

NICE said Vumerity is likely to be as effective as dimethyl fumarate, but with the added benefit of causing fewer gastrointestinal side effects.

The UK list price of Vumerity is $1,900 per pack, which consists of 120 capsules containing 231 mg each. The discounted price for NHS coverage was not disclosed.